Company
Merus N.V.
Headquarters: Utrecht, Netherlands
Employees: 87
CEO: Dr. Sven Ante Lundberg M.D.
Market Cap
$4.01 Billion
USD as of July 1, 2025
Merus N.V. Categories
Netherlands Healthcare BiotechnologyNetherlands Healthcare Netherlands Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | $54.7 M |
| EBITDA | $-298,552,992 |
| Gross Profit TTM | $-9,509,000 |
| Profit Margin | 0.00% |
| Operating Margin | -285.94% |
| Quarterly Revenue Growth | 235.80% |
Stocks & Indices
Merus N.V. has the following listings and related stock indices.
Stock: NASDAQ: MRUS wb_incandescent
Stock: FSX: 2GH wb_incandescent